Sep 30, 2026
Immutep Receives ~A$0.86 Million R&D Tax Incentive
Sep 21, 2026
Change to American Depositary Share Ratio
Sep 11, 2026
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
Jul 30, 2026
Immutep Quarterly Activities Report Q4 FY26
Jul 24, 2026
Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Jul 14, 2026
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
Jul 13, 2026
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
Jun 04, 2026
Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026
May 28, 2026
Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
Apr 30, 2026
Immutep Quarterly Activities Report Q3 FY26
Immutep Receives Nasdaq Notice of Bid Price Deficiency
Apr 22, 2026
Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
